お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
989704

中枢神経系治療薬の市場動向・市場シェア・市場規模の予測 (2021-2028年):疾患 (神経血管疾患・CNS外傷・メンタルヘルス・神経変性疾患・感染症)・地域別

Central Nervous System Therapeutic Market Size, Share & Trends Analysis Report By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases), By Region, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
中枢神経系治療薬の市場動向・市場シェア・市場規模の予測 (2021-2028年):疾患 (神経血管疾患・CNS外傷・メンタルヘルス・神経変性疾患・感染症)・地域別
出版日: 2021年02月08日
発行: Grand View Research, Inc.
ページ情報: 英文 120 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の中枢神経系治療薬の市場規模は予測期間中7.4%のCAGRで推移し、2028年には2050億米ドルの規模に成長すると予測されています。アンメットニーズの存在や疾病負担軽減のための政府による取り組みなどの要因が同市場の成長を推進する見通しです。

当レポートでは、世界の中枢神経系治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、疫学的動向、パイプラインの分析、市場規模の推移・予測、疾患・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

  • 市場の分類
  • 普及・成長の見通しマッピング
  • 規制の枠組み
  • パイプライン分析
  • 疫学研究

第4章 産業の見通し

  • 市場成長推進因子の分析
  • 市場成長阻害因子の分析

第5章 事業環境の分析

  • SWOT分析
  • ポーターのファイブフォース分析

第6章 競合分析

  • 主な取引・戦略的提携
  • 主要企業・近年の展開・影響分析
  • 公開企業
  • 非公開企業

第7章 市場予測・動向分析:疾患別

  • 神経血管疾患
  • メンタルヘルス
    • 不安障害
    • 気分障害
    • てんかん
    • 精神病性障害
    • その他
  • 変性疾患
    • アルツハイマー病
    • パーキンソン病
    • 多発性硬化症
    • ハンチントン病
    • 筋萎縮性側索硬化症
    • その他
  • CNS外傷
  • 感染症
  • CNSがん
  • その他

第8章 市場予測・動向分析:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • スペイン
    • フランス
    • イタリア
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第9章 企業プロファイル

図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 Pipeline Analysis
  • Table 3 Epidemiology
  • Table 4 North America CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 5 North America CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 6 U.S. CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 7 Canada CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 8 Europe CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 9 Europe CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 10 U.K. CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 11 France CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 12 Spain CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 13 Italy CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 14 Germany CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 15 Asia Pacific CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 16 Asia Pacific CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 17 Japan CNS Therapeutics Market, By Disease 2017 - 2028 (USD Million)
  • Table 18 China CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 19 India CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 20 Australia CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 21 South Korea CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 22 Latin America CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 23 Latin America CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 24 Brazil CNS Therapeutics Market, By Disease 2017 - 2028 (USD Million)
  • Table 25 Mexico CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 26 Argentina CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 27 Middle East & Africa CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 28 Middle East & Africa CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 29 South Africa CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 30 Saudi Arabia CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 31 UAE CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 CNS therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 CNS therapeutics market snapshot
  • Fig. 10 CNS therapeutics market driver impact
  • Fig. 11 CNS therapeutics market restraint impact
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 SWOT analysis, by factor (political & legal economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 CNS therapeutics market: Disease outlook and key takeaways
  • Fig. 16 CNS therapeutics market: Disease movement analysis
  • Fig. 17 Disease segment dashboard
  • Fig. 18 Neurovascular diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 19 CNS trauma market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 20 Mental health market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 21 Anxiety disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 22 Epilepsy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 23 Mood disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 24 Psychotic disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 25 Other mental health market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 26 Neurodegenerative diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 30 Huntington's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 31 Amyotrophic lateral sclerosis market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 32 Other neurodegenerative diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 33 Infectious diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 34 CNS cancer market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 36 CNS therapeutics market: Regional outlook and key takeaways
  • Fig. 37 Regional outlook, 2020 & 2028 (USD Million)
  • Fig. 38 Regional market dashboard
  • Fig. 39 North America
  • Fig. 40 North America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 41 U.S.
  • Fig. 42 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 43 Canada
  • Fig. 44 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 45 Europe
  • Fig. 46 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 47 Germany
  • Fig. 48 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 49 U.K.
  • Fig. 50 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 51 Spain
  • Fig. 52 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 53 France
  • Fig. 54 France market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 55 Italy
  • Fig. 56 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 57 Asia Pacific
  • Fig. 58 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 59 Japan
  • Fig. 60 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 61 China
  • Fig. 62 China market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 63 India
  • Fig. 64 India market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 65 South Korea
  • Fig. 66 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 67 Australia
  • Fig. 68 Australia market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 77 Middle East & Africa
  • Fig. 78 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 79 South Africa
  • Fig. 80 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 81 UAE
  • Fig. 82 UAE market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 83 Saudi Arabia
  • Fig. 84 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
目次
Product Code: GVR-1-68038-516-8

Central Nervous System Therapeutic Market Growth & Trends

The global central nervous system therapeutic market size is expected to reach USD 205.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2021 to 2028. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo's zinc finger platform to develop therapies for Alzheimer's disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Central Nervous System Therapeutic Market Report Highlights

  • The neurodegenerative diseases segment accounted for the largest revenue share of nearly 40.0% in 2020 and is anticipated to maintain its dominance over the forecast period
  • Pipeline candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are anticipated to drive the neurodegenerative disorder segment from 2021 to 2028
  • The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
  • In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
  • North America held a majority of share in 2020 due to high awareness level in the region and better reimbursement scenario

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates and Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity flow approach
      • 1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Tables

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Central Nervous System Therapeutics Market Variables, Trends & Scope

  • 3.1 Market Segmentation
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.4 Regulatory Framework
  • 3.5 Pipeline Analysis
  • 3.6 Epidemiology Study

Chapter 4 Central Nervous System Therapeutics Market - Industry Outlook

  • 4.1 Market Driver Analysis
    • 4.1.1 Increasing Prevalence of CNS Disorders
    • 4.1.2 Presence of Strong Pipeline Drugs
    • 4.1.3 Introduction of a Novel Drug Delivery Systems in CNS
  • 4.2 Market Restraint Analysis
    • 4.2.1 High Treatment Cost
    • 4.2.2 Lack of Neurologists and Neurosurgeons

Chapter 5 Business Environment Analysis

  • 5.1 SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 5.2 Porter's Five Forces Analysis

Chapter 6 Competitive Analysis

  • 6.1 Major Deals & Strategic Alliances
  • 6.2 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.2.1 Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
    • 6.2.3 Innovators
    • 6.2.4 List of Key Distributors and Channel Partners
    • 6.2.5 Key Company Market Share Analysis, 2020
  • 6.3 Public Companies
    • 6.3.1 Company Market Position Analysis
    • 6.3.2 Competitive Dashboard Analysis
  • 6.4 Private Companies
    • 6.4.1 List of Key Emerging Companies /Technology Disruptors/Innovators
    • 6.4.2 Regional Network Map

Chapter 7 Central Nervous System Therapeutics Market - Segment Analysis, By Disease, 2017 - 2028 (USD Million)

  • 7.1 Central Nervous System Therapeutics Market, Disease Outlook Key Takeaways
  • 7.2 Central Nervous System Therapeutics Market: Disease Movement Analysis
  • 7.3 Neurovascular Diseases
    • 7.3.1 Neurovascular Disease Treatment Market, 2017 - 2028 (USD Million)
  • 7.4 Mental Health
    • 7.4.1 Mental Health Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.2 Anxiety Disorders
      • 7.4.2.1 Anxiety Disorders Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.3 Mood disorders
      • 7.4.3.1 Mood Disorder Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.4 Epilepsy
      • 7.4.4.1 Epilepsy Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.5 Psychotic Disorders
      • 7.4.5.1 Psychotic Disorders Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.6 Others
      • 7.4.6.1 Others Market, 2017 - 2028 (USD Million)
  • 7.5 Degenerative Disorders
    • 7.5.1 Degenerative Disorders Treatment Market, 2017 - 2028 (USD million)
    • 7.5.2 Alzheimer's Disease
      • 7.5.2.1 Alzheimer's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.3 Parkinson's Disease
      • 7.5.3.1 Parkinson's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.4 Multiple Sclerosis
      • 7.5.4.1 Multiple Sclerosis Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.5 Huntington's Disease
      • 7.5.5.1 Huntington's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.6 Amyotrophic Lateral Sclerosis
      • 7.5.6.1 Amyotrophic Lateral Sclerosis Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.7 Others
      • 7.5.7.1 Others Treatment Market, 2017 - 2028 (USD Million)
  • 7.6 CNS Trauma
    • 7.6.1 CNS Trauma Treatment Market, 2017 - 2028 (USD Million)
  • 7.7 Infectious Diseases
    • 7.7.1 Infectious Diseases Treatment Market, 2017 - 2028 (USD Million)
  • 7.8 CNS Cancer
    • 7.8.1 Cancer Treatment Market, 2017 - 2028 (USD Million)
  • 7.9 Others
    • 7.9.1 Others Treatment Market, 2017 - 2028 (USD Million)

Chapter 8 Central Nervous System Therapeutics Market- Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 8.1 Central Nervous System Therapeutics Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 North America, SWOT Analysis
    • 8.2.2 North America Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.2.3 U.S.
      • 8.2.3.1 U.S. Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.2.4 Canada
      • 8.2.4.1 Canada Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe, SWOT Analysis
    • 8.3.2 Europe Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.3 Germany
      • 8.3.3.1 Germany Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.4 U.K.
      • 8.3.4.1 U.K. Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.5 Spain
      • 8.3.5.1 Spain Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.6 France
      • 8.3.6.1 France Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.7 Italy
      • 8.3.7.1 Italy Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific, SWOT Analysis
    • 8.4.2 Asia Pacific Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.3 Japan
      • 8.4.3.1 Japan Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.4 China
      • 8.4.4.1 China Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.5 India
      • 8.4.5.1 India Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.6 South Korea
      • 8.4.6.1 South Korea Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.8 Australia
      • 8.4.8.1 Australia Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America, SWOT Analysis
    • 8.5.2 Latin America Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.3 Brazil
      • 8.5.3.1 Brazil Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.4 Mexico
      • 8.5.4.1 Mexico Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.5 Argentina
      • 8.5.5.1 Argentina Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.6 Middle East & Africa
    • 8.6.1 Middle East & Africa, SWOT Analysis
    • 8.6.2 Middle-East & Africa Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.3 South Africa
      • 8.6.3.1 South Africa Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.4 Saudi Arabia
      • 8.6.4.1 Saudi Arabia Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.5 UAE
      • 8.6.5.1 UAE Market Estimates and Forecast, 2017 - 2028 (USD Million)

Chapter 9 Company Profile

  • 9.1 Company Profiles
    • 9.1.1 Biogen
      • 9.1.1.1 Company overview
      • 9.1.1.2 Financial performance
      • 9.1.1.3 Product benchmarking
      • 9.1.1.4 Strategic initiatives
    • 9.1.2 Otsuka Pharmaceutical Co., Ltd.
      • 9.1.2.1 Company overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Product benchmarking
      • 9.1.2.4 Strategic initiatives
    • 9.1.3 Eli Lilly and Company
      • 9.1.3.1 Company overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Product benchmarking
      • 9.1.3.4 Strategic initiatives
    • 9.1.4 Merck & Co.
      • 9.1.4.1 Company overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Product benchmarking
      • 9.1.4.4 Strategic initiatives
    • 9.1.5 Astra Zeneca
      • 9.1.5.1 Company overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Product benchmarking
      • 9.1.5.4 Strategic initiatives
    • 9.1.6 Shire PLC
      • 9.1.6.1 Company overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Product benchmarking
      • 9.1.6.4 Strategic initiatives
    • 9.1.7 Novartis AG
      • 9.1.7.1 Company overview
      • 9.1.7.2 Financial performance
      • 9.1.7.3 Product benchmarking
      • 9.1.7.4 Strategic initiatives
    • 9.1.8 Teva Pharmaceutical Industries Ltd.
      • 9.1.8.1 Company overview
      • 9.1.8.2 Financial performance
      • 9.1.8.3 Product benchmarking
      • 9.1.8.4 Strategic initiatives
    • 9.1.9 Johnson & Johnson Services, Inc.
      • 9.1.9.1 Company overview
      • 9.1.9.2 Financial performance
      • 9.1.9.3 Product benchmarking
      • 9.1.9.4 Strategic initiatives
    • 9.1.11 Pfizer, Inc.
      • 9.1.11.1 Company overview
      • 9.1.11.2 Financial performance
      • 9.1.11.3 Product benchmarking
      • 9.1.11.4 Strategic initiatives
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.